Your browser doesn't support javascript.
loading
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
Ouyang, D J; Chen, Q T; Anwar, M; Xie, N; Ouyang, Q C; Fan, P Z; Qian, L Y; Chen, G N; Zhou, E X; Guo, L; Gu, X W; Ding, B N; Yang, X H; Liu, L P; Deng, C; Xiao, Z; Li, J; Wang, Y Q; Zeng, S; Wang, Shouman; Yi, Wenjun.
Afiliação
  • Ouyang DJ; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Chen QT; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Anwar M; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Xie N; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Ouyang QC; Department of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Fan PZ; Department of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Qian LY; Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
  • Chen GN; Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
  • Zhou EX; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Guo L; Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Gu XW; Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Ding BN; Department of Breast and Thyroid Surgery, Hunan Provincial People's Hospital, Changsha, China.
  • Yang XH; Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China.
  • Liu LP; Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Deng C; Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Xiao Z; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
  • Li J; Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
  • Wang YQ; Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Zeng S; Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Wang S; Department of Internal Medicine-Oncology, Xiangya Hospital, Central South University, Changsha, China.
  • Yi W; Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China.
Front Pharmacol ; 12: 682568, 2021.
Article em En | MEDLINE | ID: mdl-34512325
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2021 Tipo de documento: Article